Literature DB >> 20620852

2009 H1N1 influenza pandemic.

Teri Moser Woo1.   

Abstract

The 2009 H1N1 influenza pandemic took health care workers worldwide by surprise. Early in the course of the pandemic it was determined that children and pregnant women were at high risk of increased morbidity and mortality from the novel influenza virus. The Centers for Disease Control and Prevention and state and local public health officials quickly rallied to develop treatment guidelines for the new strain of influenza A, including emergency approvals for off-label use of some antiviral drugs. Prevention of the spread of influenza via vaccination and environmental controls is critical to the health of children. The 2009 H1N1 influenza virus emerged too late to be included in the 2009/2010 seasonal influenza vaccine, so production of a monovalent vaccine was set in motion. Five months from when the first cases of novel H1N1 appeared in Mexico and the United States, a vaccine was being distributed to high-risk patients. Looking ahead to the 2010/2011 influenza season, it is difficult to predict 2009 H1N1 activity. The 2010/2011 seasonal influenza vaccine will include the 2009 H1N1 strain, so it is critical to get all children vaccinated early in the flu season. Copyright 2010 National Association of Pediatric Nurse Practitioners. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20620852     DOI: 10.1016/j.pedhc.2010.05.001

Source DB:  PubMed          Journal:  J Pediatr Health Care        ISSN: 0891-5245            Impact factor:   1.812


  2 in total

1.  Model-Based Recursive Partitioning of Patients' Return Visits to Multispecialty Clinic During the 2009 H1N1 Pandemic Influenza (pH1N1).

Authors:  Osaro Mgbere; Salma Khuwaja
Journal:  Online J Public Health Inform       Date:  2020-05-16

2.  Pandemic influenza (A/H1N1) vaccine uptake among French private general practitioners: a cross sectional study in 2010.

Authors:  Pierre Verger; Rémi Flicoteaux; Michael Schwarzinger; Luis Sagaon-Teyssier; Patrick Peretti-Watel; Odile Launay; Remy Sebbah; Jean-Paul Moatti
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.